View Older Stories View More Recent Stories
-
Evercore ISI Resumes Waters Corp. (WAT) at In Line
-
Waters Corp. (WAT) call put ratio 1 calls to 2.9 puts with a focus on ATM February puts
-
BD completes spin-off and merger of biosciences unit with Waters Corp
-
Stifel Reiterates Hold Rating on Waters Corp. (WAT)
-
Waters Corp. (WAT) Tops Q4 EPS by 2c, provides guidance
-
Waters shareholders approve BD biosciences unit combination
-
HSBC Starts Waters Corp. (WAT) at Buy
-
Guggenheim Starts Waters Corp. (WAT) at Buy
-
William Blair Starts Waters Corp. (WAT) at Outperform
-
Wolfe Research Upgrades Waters Corp. (WAT) to Outperform
-
KeyBanc on Life Sciences Tools & Services: 'We Highlight Our Favored 2026 "Tools" Stocks'
-
Morgan Stanley Starts Waters Corp. (WAT) at Equalweight, 'High Quality Core Business but BDX Deal Bears Monitoring'
-
KeyBanc: White House GLP-1 Deals Boost Growth Potential for Key Suppliers
-
Waters Corp. (WAT) PT Raised at TD Cowen on Core Business Strength
-
Waters Corp. (WAT) PT Raised to $375 at BofA Securities
-
Waters Corp. (WAT) call put ratio 1.4 calls to 1 put as share price up 7%
-
Waters Corp. (WAT) Tops Q3 EPS by 19c ; Offers Guidance
-
Waters Corp. (WAT) May options active as share price up 1.5%
-
Rothschild Redburn Starts Waters Corp. (WAT) at Buy
-
Stifel Reiterates Hold Rating on Waters Corp. (WAT)
-
KeyBanc Takeaways from This Year's BioProcess International Conference
-
KeyBanc Reiterates Overweight Rating on Waters Corp. (WAT)
-
Waters Corp. (WAT) PT Lowered to $322 at TD Cowen
-
Waters Corp. (WAT) PT Lowered to $360 at Bernstein SocGen Group
-
Waters Corp. (WAT) PT Lowered to $385 at Jefferies, 'Solid Beat & Raise Still Embeds Upside'
-
Waters Corp. (WAT) Tops Q2 EPS by 1c, provides guidance
-
Waters Corp. (WAT) PT Lowered to $333 at TD Cowen
-
Bernstein on Waters Corp. (WAT): 'Is It Really That Bad?'
-
UBS Reiterates Neutral Rating on Waters Corp. (WAT)
-
Stifel Reiterates Hold Rating on Waters Corp. (WAT)
-
Waters Corp. (WAT) PT Lowered to $330 at BofA Securities
-
Waters to merge with BD's biosciences unit in $17.5 billion deal
-
Waters Corp. (WAT) PT Raised to $465 at Scotiabank
-
Bernstein on US Life Science Tools & Diagnostics: 'Why We're More Bullish...'
-
Bernstein SocGen Group Reiterates Outperform Rating on Waters Corp. (WAT)
-
Waters Corp. (WAT) unveils Alliance iS HPLC System Software 2.0
-
KeyBanc: 'Waters Corp. (WAT) Likely to Continue Outperforming Peers'
-
UBS Reiterates Neutral Rating on Waters Corp. (WAT)
-
Waters Corp. (WAT) Tops Q1 EPS by 3c; raises guidance
-
KeyBanc Upgrades Waters Corp. (WAT) to Overweight
-
Baird Upgrades Waters Corp. (WAT) to Outperform
-
Stifel Reiterates Hold Rating on Waters Corp. (WAT)
-
TD Cowen on Waters Corp. (WAT): 'Impressive Showcase of Strategy, Execution, Growth & Margins'
-
Waters Corp. (WAT) PT Raised to $430 at Leerink Partners
-
Buy the earnings dip in this stock: Bernstein
-
Bernstein on Waters Corp. (WAT): 'Buy the Dip'
-
Waters Corp. (WAT) PT Lowered to $410 at BofA Securities
-
Waters Corp. (WAT) Tops Q4 EPS by 7c; offers guidance
-
TD Cowen: 'Assessing Impact of US Ban on China Exports for LCMS & Flow Cyt Instruments'
-
Waters Corp. (WAT) call put ratio 2 calls to 1 put as share price down 2.2%

